SHANGHAI, China, January 2, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (the \u201csNDA\u201d) for toripalimab (trade name: TUOYI\u00ae, product code: JS001) in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (\u201cNSCLC\u201d) has been approved by the National Medical Products Administration. This is the first approved perioperative therapy for lung cancer in China and the second worldwide.<\/p>\n\n\n\n
Lung cancer is currently the world\u2019s second most prevalent malignant tumor, with the highest mortality rate. According to the World Health Organization, in 2020, the number of new lung cancer cases in China amounted to 816,000, accounting for 17.9% of all new cancer cases in China. In the same year, the number of lung cancer deaths in China amounted to 715,000, accounting for 23.8% of all cancer deaths in China. NSCLC is a major subtype of lung cancer, accounting for approximately 85% of all cases. Amongst these patients, 20%-25% are surgically resectable at first diagnosis, but even after radical surgical treatment, 30%-55% of these patients suffer from post-surgical recurrence and death. Radical surgery in combination with chemotherapy is a way to prevent recurrence, but chemotherapy alone, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefits and can only raise patients\u2019 5-year survival rate by approximately 5%.<\/p>\n\n\n\n
The approval of the sNDA is primarily based on data from the NEOTORCH study (NCT04158440), a randomized, double-blind, placebo-controlled, multi-center phase III clinical study led by Professor Shun LU of Shanghai Chest Hospital of the Shanghai Jiao Tong University School of Medicine. Conducted across 56 centers nationwide, NEOTORCH is the world\u2019s first phase III clinical study of anti-PD-1 monoclonal antibody for NSCLC perioperative treatment (including neoadjuvant and adjuvant) with positive event-free survival (\u201cEFS\u201d) results.<\/p>\n\n\n\n
A total of 404 patients with stage IIIA-IIIB NSCLC were enrolled in the study and randomized at a ratio of 1:1 to receive toripalimab in combination with chemotherapy (n=202) or placebo in combination with chemotherapy (n=202). The patients received three cycles of pre-operative treatment and one cycle of post-operative treatment with toripalimab or placebo in combination with chemotherapy (paclitaxel in combination with cisplatin for patients with squamous NSCLC, while pemetrexed in combination with cisplatin for patients with non-squamous NSCLC), respectively; they then received either toripalimab or placebo for 13 cycles of adjuvant therapy.<\/p>\n\n\n\n
The latest study results of the NEOTORCH study were announced in an oral presentation at the 2023 American Society of Clinical Oncology (\u201cASCO\u201d) Plenary Series held in April, as well as the 2023 ASCO annual meeting. The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy for perioperative treatment of resectable stage III NSCLC could significantly extend patient EFS (median EFS as assessed by investigators: not reached vs. 15.1 months, P < 0.0001), and reduce the risk of disease recurrence, progression, or death in patients by 60% (HR=0.40, 95% CI: 0.277-0.565), and EFS benefits was observed in all key toripalimab subgroups, regardless of PD-L1 expression status and histologic type (squamous or non-squamous). Major pathological remission (MPR) rates and pathological complete remission (pCR) rates were significantly better in the toripalimab group, 48.5% vs 8.4% (P < 0.0001) and 24.8% vs 1.0% (P < 0.0001), respectively, and the overall survival (OS) of the toripalimab group also showed a clear trend of benefit. In terms of safety, the incidences of treatment-emergent adverse events (TEAEs) were similar in both groups, and no new safety signals were observed.<\/p>\n\n\n\n
\u201cThe NEOTORCH study has pioneered the world\u2019s first \u20183+1+13\u2019 perioperative treatment model for NSCLC, which has resulted in nearly 25 times higher rates of pCR and 6 times higher rates of MPR compared to patients treated with chemotherapy alone,\u201d said, Professor Shun LU of Shanghai Chest Hospital of the Shanghai Jiao Tong University School of Medicine<\/strong>. \u201cAdditionally, this model has achieved elevated rates of R0 resection without increasing the surgical risks. Post-surgery, this regimen requires one cycle of immunotherapy combined with chemotherapy, along with a year-long maintenance treatment with toripalimab, which further eliminates patients\u2019 residual lesions and extends benefits to those who did not achieve pCR. The EFS hazard ratio (HR) of 0.40 stands as the most substantial reduction in HR reported in perioperative immunotherapy studies to date. We believe that the approval of China\u2019s first perioperative immunotherapy indication for lung cancer will significantly impact the long-term survival prospects for stage III NSCLC patients in China, opening up new avenues for potential treatments, drastically improving the standard of NSCLC treatment in China, and setting a new benchmark for perioperative treatment.\u201d <\/p>\n\n\n\n \u201cThis approval of the new perioperative lung cancer indication signifies the expansion of toripalimab\u2019s treatment population from late-stage to early-stage cancer patients. One of the first domestic pharmaceutical companies to initiate clinical trials for perioperative immunotherapy, Junshi Biosciences entered the perioperative immunotherapy arena very early on and now holds the broadest spectrum of indications in China. Presently, cancer immunotherapy has evolved into the standard treatment for various late-stage cancers, we are confident that this innovative therapy will lead to breakthrough changes in early cancer treatment and become the preferred treatment option for patients seeking long-term benefits,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences<\/strong>.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" The supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer has been approved by the National Medical Products Administration<\/p>\n","protected":false},"author":3,"featured_media":2629,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n